Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update

Carisma Therapeutics, Inc. (NASDAQ:CARM) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 596,500 shares, a decline of 16.5% from the January 31st total of 714,400 shares. Approximately 2.9% of the company’s shares are short sold. Based on an average daily volume of 358,800 shares, the short-interest ratio is presently 1.7 days.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CARM. Wexford Capital LP grew its holdings in Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Carisma Therapeutics by 11.9% in the 4th quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after buying an additional 24,600 shares during the last quarter. Finally, Barclays PLC grew its holdings in Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares during the last quarter. Institutional investors and hedge funds own 44.27% of the company’s stock.

Carisma Therapeutics Stock Down 1.3 %

CARM opened at $0.40 on Friday. Carisma Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $2.67. The business has a 50-day moving average of $0.46 and a 200-day moving average of $0.75. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The company has a market capitalization of $16.49 million, a PE ratio of -0.25 and a beta of 1.55.

Wall Street Analyst Weigh In

CARM has been the subject of a number of analyst reports. Evercore ISI restated an “in-line” rating and issued a $0.70 price target (down previously from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. D. Boral Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Carisma Therapeutics in a research report on Monday, January 13th. BTIG Research lowered Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Baird R W lowered Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Robert W. Baird lowered Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $10.00 to $1.00 in a research report on Thursday, December 12th. Five equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.94.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.